Search results for "ductal carcinoma"

showing 10 items of 19 documents

Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis

2018

Abstract Background Ki-67 is a marker of proliferating cells; in this meta-analysis we aimed to examine whether Ki-67 expression can predict recurrence rates of breast ductal carcinoma in situ (DCIS). Materials and Methods This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were sought in MEDLINE up to April 30, 2017. Random effects (DerSimonian–Laird) models were used for the calculation of pooled relative risk (RR) estimates; meta-regression analysis was also performed. Separate analyses were performed according to Ki-67 expression cutoff levels, invasiveness of recurrence,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsRisk Assessment03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansMeta-regressionBreastMastectomybiologybusiness.industryDuctal carcinomaPrognosismedicine.diseaseConfidence intervalCarcinoma Intraductal NoninfiltratingKi-67 Antigen030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMeta-analysisKi-67biology.proteinFemaleRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessCohort studyClinical Breast Cancer
researchProduct

Aberrantly Expressed Embryonic Protein NODAL Alters Breast Cancer Cell Susceptibility to γδ T Cell Cytotoxicity

2020

Gamma delta (γδ) T cells kill transformed cells, and increased circulating γδ T cells levels correlate with improved outcome in cancer patients; however, their function within the breast tumor microenvironment (TME) remains controversial. As tumors progress, they begin to express stem-cell associated proteins, concomitant with the emergence of therapy resistant metastatic disease. For example, invasive breast cancers often secrete the embryonic morphogen, NODAL. NODAL has been shown to promote angiogenesis, therapy resistance and metastasis in breast cancers. However, to date, little is known about how this secreted protein may interact with cells in the TME. Herein we explore how NODAL in …

0301 basic medicinelcsh:Immunologic diseases. AllergyNodal ProteinAngiogenesisT cellImmunologytumor evasionTriple Negative Breast NeoplasmsBiologyMetastasis03 medical and health sciences0302 clinical medicineTumor Microenvironmentmedicineinvasive ductal carcinomaHumansImmunology and Allergygamma delta T cellsIntraepithelial LymphocytesTriple-negative breast cancerOriginal ResearchAgedAged 80 and overT-cell receptorCancerReceptors Antigen T-Cell gamma-deltaMiddle Agedmedicine.diseasegammadelta030104 developmental biologymedicine.anatomical_structureCell culturetriple negative breast cancerMICACancer researchFemaleTumor EscapeNODALNODALlcsh:RC581-607030215 immunologyFrontiers in Immunology
researchProduct

CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer.

2003

Infiltrating CD1a(+) dendritic cells (DCs) have been associated with increased survival in a number of human cancers. This study investigated DC infiltration within breast cancers and the association with survival. Classical established prognostic factors, of tumour size, lymph node status, histological grade, lympho-vascular invasion, the KI-67 (MIB-1) fraction and the Nottingham Prognostic Index (NPI) were also compared. A total of 48 breast cancer patients were followed from the time of surgery and CD1a density analysis for 5 years or until death. Our data set validated previous studies, which show a relationship between survival and the NPI (P0.001), tumour size (P0.01) and lymph node s…

AdultCancer ResearchCellular immunityPathologymedicine.medical_specialtyMammary glandBreast NeoplasmsCD1asurvivalAntigens CD1Breast cancerbreast cancerPredictive Value of Testsmental disordersmedicineHumansskin and connective tissue diseasesAntigen-presenting cellLetter to the EditorSurvival analysisAgedAged 80 and overintegumentary systembusiness.industryMolecular and Cellular PathologyCancerDendritic cellDendritic CellsDuctal carcinomaMiddle Agedmedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureOncologyCancer researchFemalebusinessBritish journal of cancer
researchProduct

PANCREATIC CARCINOMA VERSUS CHRONIC FOCAL PANCREATITIS: CONTRAST-ENHANCED POWER DOPPLER ULTRASONOGRAPHY FINDINGS

2005

Background: We assessed the potential usefulness of contrast-enhanced power Doppler ultrasonography (US) for differentiating pancreatic carcinoma from chronic focal pancreatitis. Methods: Twenty-six consecutive patients with ductal carcinoma (n=16) and chronic focal pancreatitis (n=10) underwent power Doppler US examinations before and after intravenous injection of an air-based contrast agent (Levovist, Schering, Berlin, Germany). Final diagnosis was obtained by surgery in all patients. The following parameters before and after intravenous administration of contrast agent were evaluated for each lesion: number, morphology and course of the vessels within the lesion and time to maximum dete…

AdultMalemedicine.medical_specialtyPancreatic diseasechronic focal pancreatitiUrologyContrast MediaAdenocarcinomaDiagnosis DifferentialLesionPolysaccharidesInternal medicinemedicineCarcinomaHumansRadiology Nuclear Medicine and imagingAgedRetrospective Studiespower Doppler ultrasonographyRadiological and Ultrasound Technologypancreatic carcinomabusiness.industryultrasoundUltrasoundGastroenterologyUltrasonography DopplerGeneral MedicineMiddle AgedDuctal carcinomaHepatologymedicine.diseasePancreatic NeoplasmsPancreatitisChronic DiseaseInjections IntravenousPancreatitisFemaleRadiologymedicine.symptombusinessBlood Flow Velocitycontrast-enhanced ultrasoundContrast-enhanced ultrasound
researchProduct

Transforming Growth Factor Beta 1 Serum Levels in Patients with Preinvasive and Invasive Lesions of the Breast

2004

Transforming growth factor beta (TGF-beta)1 is thought to be involved in breast carcinogenesis. TGF-beta1 acts in an antiproliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-beta1 in breast cancer. We investigated TGF-beta1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-beta1 seru…

AdultOncology0301 basic medicinemedicine.medical_specialtyPathologyCancer ResearchMammary glandClinical BiochemistryCA 15-3Breast NeoplasmsPathology and Forensic MedicineTransforming Growth Factor beta103 medical and health sciencesBreast cancer0302 clinical medicineTransforming Growth Factor betaInternal medicinemedicineHumansNeoplasm Invasivenessskin and connective tissue diseasesEstrogen Receptor StatusAgedNeoplasm StagingAged 80 and overPredictive markerbusiness.industryMiddle AgedDuctal carcinomamedicine.diseaseFibroadenomamedicine.anatomical_structure030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisbusinessThe International Journal of Biological Markers
researchProduct

Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer

2003

The chemokine monocyte chemoattractant protein (MCP)-1 is thought to be involved in breast carcinogenesis. We evaluated MCP-1 serum levels in patients with breast cancer (n = 135), ductal carcinoma in situ (DCIS) I-III (n = 30), benign breast lesions (n = 143) and in healthy women (n = 27). We determined the value of MCP-1 serum levels as a differentiation marker between malignant, preinvasive and benign breast diseases and as a predictive marker for the biological phenotype of breast carcinoma. Median (range) MCP-1 serum levels in patients with breast cancer, DCIS I-III, benign breast lesions and healthy women were 200 (57-692) pg/ml, 194 (58-525) pg/ml, 174 (39-529) pg/ml and 175 (67-425)…

AdultOncologymedicine.medical_specialtyCA 15-3Breast NeoplasmsBreast DiseasesBreast cancerReference ValuesInternal medicineBiomarkers TumormedicineCarcinomaHumansNeoplasm Invasivenessskin and connective tissue diseasesLymph nodeChemokine CCL2AgedRetrospective StudiesPredictive markerbusiness.industryCase-control studyGeneral MedicineMiddle AgedDuctal carcinomamedicine.diseaseCarcinoma Intraductal NoninfiltratingCell Transformation NeoplasticPhenotypemedicine.anatomical_structureCase-Control StudiesLymphatic MetastasisFemaleBreast carcinomabusinessTumor Biology
researchProduct

Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen.

2003

Tamoxifen exhibits agonistic properties on the uterus. We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery.

AdultSelective Estrogen Receptor Modulatorsmedicine.medical_specialtyAntineoplastic Agents HormonalEndometriosisUterusEndometriosisBreast NeoplasmsCarcinomamedicineHumansskin and connective tissue diseasesGynecologybusiness.industryCarcinoma Ductal BreastObstetrics and GynecologyDuctal carcinomamedicine.diseaseAntiestrogenAbdominal PainOvarian CystsTamoxifenmedicine.anatomical_structureReproductive MedicinePremenopauseAcute abdomenAcute DiseaseFemalemedicine.symptombusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non-tumoral adjacent counterparts.

2006

According to recent statistics, breast cancer remains one of the leading causes of death among women in Western countries. Breast cancer is a complex and heterogeneous disease, presently classified into several subtypes according to their cellular origin. Among breast cancer histotypes, infiltrating ductal carcinoma represents the most common and potentially aggressive form. Despite the current progress achieved in early cancer detection and treatment, including the new generation of molecular therapies, there is still need for identification of multiparametric biomarkers capable of discriminating between cancer subtypes and predicting cancer progression for personalized therapies. One esta…

CA15-3Oncologymedicine.medical_specialtybusiness.industryProteomic ProfilingClinical BiochemistryDiseasemedicine.diseaseBREAST CANCER PROTEOMICSCellular originBreast cancerInfiltrating ductal carcinomaInternal medicinemedicineBreast carcinogenesisEarly Cancer Detectionskin and connective tissue diseasesbusiness
researchProduct

Cytogenetic study of angiosarcoma of the breast.

1994

Angiosarcoma of the breast is quite rare, and the development of cutaneous angiosarcoma after segmental mastectomy and radiation therapy is even less common. A cytogenetic analysis of a mammary angiosarcoma arising in a breast after previous irradiation and segmental mastectomy for infiltrating ductal carcinoma revealed multiple clonal rearrangements involving chromosomes X, 1, 2, 3, 4, 5, 6, 7, 8, 9, 15, 17, 20, and 22. No cytogenetically analyzed angiosarcomas of the breast have been reported before. Genes Chromosom Cancer 10:210–212 (1994). © 1994 Wiley-Liss, Inc.

Chromosome AberrationsCancer Researchmedicine.medical_treatmentCarcinoma Ductal BreastHemangiosarcomaCancerBreast NeoplasmsNeoplasms Second PrimarySegmental MastectomyBiologyMiddle Agedmedicine.diseasedigestive system diseasesRadiation therapyInfiltrating ductal carcinomaKaryotypingGeneticsCancer researchmedicineHumansAngiosarcomaFemaleneoplasmsGenes, chromosomescancer
researchProduct

Benign, preinvasive and invasive ductal breast lesions. A comparative study with quantitative techniques: morphometry, image- and flow cytometry.

1999

The histological distinction between ductal hyperplasia of the breast, atypical ductal hyperplasia and ductal carcinoma in situ is difficult and subjective. To gain a better understanding of these lesions, we performed a comparative study comprising 20 cases of ductal hyperplasia without atypia, 20 cases of ductal hyperplasia with atypia, and 30 cases of ductal carcinoma in situ (well-, moderately- and poorly-differentiated), using quantitative techniques: image cytometry analysis, morphometry and DNA analysis, and DNA flow cytometry. Our results confirm that the mean nuclear area and volume progressively decreased from ductal carcinoma in situ to ductal hyperplasia without atypia. The diff…

In situPathologymedicine.medical_specialtyBreast NeoplasmsCell SeparationPathology and Forensic MedicineFlow cytometryAtypiaImage Processing Computer-AssistedMedicineHumansDuctal Hyperplasiaskin and connective tissue diseasesneoplasmsDNA Image CytometryImage CytometryCell NucleusPloidiesintegumentary systemmedicine.diagnostic_testbusiness.industryCarcinoma Ductal BreastCell BiologyDNA NeoplasmDuctal carcinomaHyperplasiamedicine.diseaseFlow Cytometrybody regionsImage CytometryFemalebusinessPrecancerous ConditionsCarcinoma in SituPathology, research and practice
researchProduct